| Literature DB >> 2107174 |
Abstract
This article provides us with background information on the disease. Clinical features, variants and classification, laboratory findings, and pathology are discussed. Knowledge of the disease's pathogenesis has increased recently and specific causes discussed are predisposing factors, triggering agents, endothelial damage, defective PGI2 bioavailability, FVIII/vWF multimeric structure abnormalities, platelet activation, and hemolytic anemia. Proposed specific therapies discussed are steroids, heparin, antiplatelet agents, prostacyclin, splenectomy, immunosuppressive agents, plasma infusion, and plasma exchange.Entities:
Keywords: Biology; Blood Coagulation Effects; Cyclophosphamide; Diseases; Embolism; Endocrine System; Hematological Effects; Hemic System; Hemoglobin Level; Ingredients And Chemicals; Mustard Compounds; Nitrogen Mustard Compounds; Organic Chemicals; Physiology; Prostaglandins; Prostaglandins, Synthetic; Renal Effects; Signs And Symptoms; Thromboembolism; Thrombosis--history; Treatment; Urogenital Effects; Urogenital System; Vascular Diseases
Mesh:
Substances:
Year: 1990 PMID: 2107174
Source DB: PubMed Journal: Hematol Oncol Clin North Am ISSN: 0889-8588 Impact factor: 3.722